Behcet Disease
Behçet disease (BD) is a complex autoimmune disorder characterized by recurrent oral and genital ulcers, skin lesions, uveitis, and systemic involvement. Our company is at the forefront of drug and therapy development services for Behçet disease, offering innovative solutions to address the various aspects of this challenging condition.
Introduction to Behcet Disease
Behçet disease, also known as Behçet syndrome, was first described by a Turkish dermatologist, Hulusi Behçet, in 1937. It is a multisystemic inflammatory disorder that primarily affects the blood vessels, leading to vasculitis and subsequent organ damage. The major histocompatibility complex (MHC) class I molecule HLA-B51 has been strongly associated with the development of Behçet Disease, suggesting a genetic predisposition. Dysfunction of regulatory T cells and abnormal neutrophil activation are also implicated in the pathogenesis.
Fig.1 The pathogenesis of Behcet Disease. (Rodríguez-Carrio J., et al., 2021)
Therapy Discovery and Development for Behcet Disease
Behçet disease drug and therapy options aim to alleviate symptoms, reduce inflammation, and prevent disease progression. The mainstay of therapeutic for Behçet disease includes the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to relieve pain and inflammation. In recent years, targeted biologic therapies have shown promise in treating Behçet disease. Biologics, such as tumor necrosis factor-alpha (TNF-α) inhibitors and interleukin-1 (IL-1) inhibitors, specifically target the molecules involved in the inflammatory process. These medications have demonstrated efficacy in reducing disease activity and improving symptoms in some cases with Behçet disease.
At our company, we offer a range of innovative services focused on Behçet disease diagnostics and therapy development. If you would like to learn more about our therapy development services, please click on the link below.
Our Services
In order to enhance preclinical research and facilitate therapeutic advancements, our company specializes in providing customized animal models and in vitro models specifically tailored for the study of Behçet's disease. Our experienced team conducts in-depth investigations to assess the safety, efficacy, and pharmacokinetic properties of potential therapeutics. Through meticulous modeling and validation, we ensure the relevance and reliability of these models, enabling accurate translation to human studies.
Environmental Pollutants Induced Models
Environmental pollutants have been suggested as potential triggers for autoimmune diseases, including Behçet's disease. Our company offers induced model development services to investigate the effects of environmental pollutants on BD development.
Bacterial Induced Models
Bacterial infections, particularly Streptococcus sanguinis and Streptococcus pyogenes, have been associated with the development of Behçet's disease. Our company provides induced model development services to study the effects of bacterial infections on BD pathogenesis.
HSPs Induced Models
Heat shock proteins (HSPs) have been implicated in the pathogenesis of Behçet's disease. At our company, we offer induced model development services to study the effects of HSP derived peptides on Behcet disease (BD) development.
Virus Induced Models
Viral infections, such as herpes simplex virus and hepatitis C virus, have been proposed as potential triggers for Behçet's disease. By introducing specific viral strains or viral components into animal models, we can replicate the immune responses and tissue damage observed in BD cases.
At our company, we offer cell-based model development services to replicate specific aspects of BD pathology and investigate disease mechanisms. These models involve culturing and manipulating relevant cell types, such as immune cells, endothelial cells, and epithelial cells.
We provide organoid model development services to investigate Behçet's disease at a more advanced level. Organoids are self-organizing structures derived from pluripotent stem cells or adult tissue stem cells and can replicate specific organs or tissues affected by BD, such as the oral mucosa, gut, or eye.
Our expertise in developing and optimizing these models allows for high-throughput screening of drug candidates and the evaluation of their efficacy and safety profiles. Beyond the aforementioned repertoire of services and models, our expertise extends to crafting personalized solutions and designing disease models that impeccably align with your unique needs. If our comprehensive range of offerings has piqued your interest, we wholeheartedly encourage you to connect with us without any hesitation.
References
- Rodríguez-Carrio J., et al. "Behçet disease: from pathogenesis to novel therapeutic options." Pharmacological Research 167 (2021): 105593.
- Alibaz-Oner Fatma, and Haner Direskeneli. "Advances in the treatment of Behcet's disease." Current rheumatology reports 23.6 (2021): 47.